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Appropriate nutrition is an essential component of intensive care management of children 
with acute respiratory distress syndrome (ARDS) and is linked to patient outcomes. One 
out of every two children in the pediatric intensive care unit (PICU) will develop malnutri-
tion or have worsening of baseline malnutrition and present with specific micronutrient 
deficiencies. Early and adequate enteral nutrition (EN) is associated with improved 60-day 
survival after pediatric critical illness, and, yet, despite early EN guidelines, critically ill chil-
dren receive on average only 55% of goal calories by PICU day 10. Inadequate delivery 
of EN is due to perceived feeding intolerance, reluctance to enterally feed children with 
hemodynamic instability, and fluid restriction. Underlying each of these factors is large 
practice variation between providers and across institutions for initiation, advancement, 
and maintenance of EN. Strategies to improve early initiation and advancement and to 
maintain delivery of EN are needed to improve morbidity and mortality from pediatric 
ARDS. Both, over and underfeeding, prolong duration of mechanical ventilation in chil-
dren and worsen other organ function such that precise calorie goals are needed. The 
gut is thought to act as a “motor” of organ dysfunction, and emerging data regarding the 
role of intestinal barrier functions and the intestinal microbiome on organ dysfunction and 
outcomes of critical illness present exciting opportunities to improve patient outcomes. 
Nutrition should be considered a primary rather than supportive therapy for pediatric 
ARDS. Precise nutritional therapies, which are titrated and targeted to preservation of 
intestinal barrier function, prevention of intestinal dysbiosis, preservation of lean body 
mass, and blunting of the systemic inflammatory response, offer great potential for 
improving outcomes of pediatric ARDS. In this review, we examine the current evidence 
regarding dose, route, and timing of nutrition, current recommendations for provision of 
nutrition to children with ARDS, and the current literature for immune-modulating diets 
for pediatric ARDS. We will examine emerging data regarding the role of the intestinal 
microbiome in modulating the response to critical illness.
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iNTRODUCTiON
There are direct nutritive and non-nutritive benefits of feeding patients with pediatric acute respira-
tory distress syndrome (pARDS). Adequate nutrition therapy in support of protein, energy, and 
micronutrient needs prevents loss of lean body mass, improves protein turnover for production of 
acute phase and immune proteins, prevents depletion of tissue antioxidant systems which occur with 
FiGURe 1 | Metabolic response to pediatric critical illness. + Acute adaptive response; − maladaptive consequence;  increased;  decreased. 
Abbreviations: LPL, lipoprotein lipase; aa, amino acids; resp, respiratory; rbc’s, red blood cells. Adapted with permission from Graciano and Turner (25). Copyright 
from the Society of Critical Care Medicine.
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starvation, and is associated with improved 60-day mortality in 
mechanically ventilated, critically ill children (1–3). Adequate 
protein delivery prevents loss of respiratory and cardiac muscle 
function and is associated with increased ventilator-free days 
and improved mortality in pARDS (4). And, yet, median deliv-
ery of enteral nutrition (EN) remains 40–75% of goal over the 
first week of pediatric intensive care unit (PICU) hospitalization 
(3, 5–10). In addition, as protein synthesis rates are reliant upon 
adequate protein delivery, patients may not realize benefits of 
adjuvant therapies that rely on protein signaling if they fail to 
meet goal EN.
The gastrointestinal tract is a primary lymphoid organ, housing 
70% of all immune cells with the ability to alter systemic inflam-
matory responses (11–14). Non-nutritive benefits of feeding, 
therefore, include downstream reduction in pro-inflammatory 
signaling to the lung (11, 15, 16). The gastrointestinal tract is an 
important target to improve lung inflammation, during pARDS, 
and subsequent patient outcomes. The intestinal epithelial barrier 
is a single-cell monolayer, which must absorb fluids and nutri-
ents, interact with commensal organisms, and prevent entrance 
of pathogens and their toxic products (17). Intestinal barrier dys-
function has many downstream negative consequences. It is asso-
ciated with bacterial translocation, endotoxemia, organ failure, 
immune dysfunction, and lung inflammation (13, 18, 19). The 
intestinal epithelial barrier, the host microbiome, and intestinal 
immune system interaction contribute to the pathophysiology of 
pARDS and present novel therapeutic targets.
Specific nutrients provided at pharmacological doses or 
nutrition supplemented with immune-modulating factors may 
directly impact lung pro-inflammatory cytokines and neutrophil 
accumulation in the setting of pARDS (20–22). Non-nutritive 
goals of feeding with either a standard enteral formula or an 
immune-modulating formula include maintenance of intestinal 
barrier functions, to alter or attenuate the immune or inflamma-
tory responses in pARDS, and to modulate microbiome and/or 
host–microbe interactions. The host microbiome is emerging as 
an important mediator in chronic as well as acute inflammatory 
states. An understanding of the necessary and sufficient nutrition 
for each of these nutritive and non-nutritive benefits is impor-
tant to determine the minimum necessary macronutrient and 
micronutrient delivery during each phase of pARDS to optimize 
patient outcomes. Optimizing nutritional therapy to delivery the 
right nutrition to the right patient at the right time is an excellent 
opportunity to improve outcomes in pARDS.
MeTABOLiSM DURiNG PeDiATRiC 
CRiTiCAL iLLNeSS
Currently, knowledge of the normal nutritional needs of children 
and of the metabolic response to critical illness guides recom-
mendations and goals for nutritional support in pediatric patients 
(Figure 1). Critical illness and the associated inflammation and 
tissue injury alter metabolism by inducing a catabolic state, which 
may exacerbate pre-existing malnutrition (1, 23). Metabolism 
TABLe 1 | Key observational studies of the impact of nutrition and nutritional status on patient outcomes in pediatric critical illness.
Study Patient population exposure of 
interest
Outcomes
Timing, dose, route nutrition
Wong  
et al. (4)
Multicenter study of 107 children 
with ARDS
Enteral calorie 
and protein 
adequacy
Reduction in ICU mortality in patients who received adequate calories (34.6 versus 60.5%, 
p = 0.025) and adequate protein (14.3 versus 60.2%, P = 0.002) compared with those who did 
not. Patients with adequate protein intake also had more VFDs [median (interquartile range), 12 
(3.0–19.0) versus 0 (0.0–14.8) days; p = 0.005]
Mikhailov 
et al. (36)
Multicenter study of 5105 children 
1 month to 18 years with PICU 
length of stay ≥96 h
Early enteral 
nutrition
Early EN was associated with lower odds of mortality (OR 0.52; 95% CI 0.34–0.76, p = 0.001). 
No significant differences in length of stay or duration of mechanical ventilation in patients 
exposed to early EN
Mehta  
et al. (2)
Multicenter study of 1245 children 
1 month to 18 years requiring 
mechanical ventilation ≥48 h
Enteral protein 
adequacy
Adequacy of enteral protein intake was associated with lower 60-day mortality (p < 0.001)
Mehta  
et al. (3)
Multicenter study of 500 children 
1 month to 18 years requiring 
mechanical ventilation >48 h
Enteral calorie 
adequacy
A higher percentage of goal energy intake via enteral nutrition route was significantly associated 
with lower 60-day mortality (p = 0.002). Mortality was higher in patients who received PN 
(p = 0.008). Patients admitted to units that utilized a feeding protocol had a lower prevalence 
of acquired infections and this association was independent of the amount of energy or protein 
intake
Nutritional status
Bechard 
et al. (26)
Multicenter study of 1622 
mechanically ventilated children 
from 2 study cohorts
Baseline 
nutritional 
status
BMI z-score classification as underweight or obese was associated with higher risk of hospital-
acquired infections and lower likelihood of hospital discharge. Underweight children had a higher 
risk of mortality and fewer ventilator-free days
de Souza 
Menezes 
et al. (27)
Single-center prospective study 
of 385 critically ill children
Baseline 
nutritional 
status
Malnutrition (BMI z-score <−2 for weight for age, height for age, and BMI) was associated with 
greater length of mechanical ventilation and length of stay. Malnutrition was not a predictor of 
mortality
eN safety and complications
Lopez-Herce 
et al. (37)
Single-center prospective, 
observational study of 526 
critically ill children who received 
post-pyloric enteral nutrition (PEN)
Enteral  
nutrition
The stepwise multivariate logistic regression analysis showed that the most important factors 
associated with gastrointestinal complications were shock, epinephrine at a rate higher than 
0.3 μg/kg/min and hypophosphatemia
Panchal  
et al. (38)
Multicenter study of 339 children 
admitted to PICU for ≥96 h and 
on vasoactive infusions
Enteral  
nutrition
Unadjusted mortality was lower in the patients exposed to EN (6.9 versus 15.9%, p < 0.01). 
Vasoactive-inotropic score did not differ between the two groups except on day 1. No difference 
in gastrointestinal outcomes between patients who did and did not receive enteral nutrition
VFD, ventilator-free days; BMI, body mass index.
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shifts away from growth to support the production of acute phase 
proteins, enzymes, and glucose to facilitate recovery (23, 24). 
This is accomplished through glycolysis, lipolysis, and protein 
turnover with resulting hyperglycemia, ketone production, and 
breakdown of skeletal muscle protein (23, 24). This diversion of 
resources results in cessation of normal growth and development 
in pediatric patients (23, 24). Prolonged persistence of this cata-
bolic state progressively depletes the body’s nutritional resources, 
ultimately leading to muscle wasting, impaired cardiopulmonary 
function, decreased immune response, and poor wound healing 
(Figure 1). Pediatric patients (especially those with pre-existing 
nutritional, cardiopulmonary, or muscular disease) are particu-
larly susceptible to these adverse sequelae due to their limited 
macronutrient and micronutrient reserves. In the setting of 
pARDS, this loss of lean body mass and diaphragmatic function 
is likely to amplify the severity of the patient’s respiratory failure 
and prolong ventilator dependence.
PRe-eXiSTiNG NUTRiTiONAL STATUS 
MeDiATeS PATieNT OUTCOMeS
Patients who are undernourished prior to their critical illness 
experience worse outcomes (Table 1) (26). High quality research 
to understand how adequacy of nutrition delivery and premorbid 
nutritional status influences outcomes of pARDS is limited; how-
ever, pre-illness nutritional status and adequacy of macronutrient 
delivery early in critical illness are well established as risk factors 
for morbidity and mortality of critically ill patients in neonatal 
and pediatric populations (2, 3, 7, 10, 26–31). Malnutrition is 
both prevalent and incident in children hospitalized in the PICU; 
30% of children admitted to the PICU have pre-existing acute or 
chronic malnutrition, and up to 58% of patients are discharged 
from the PICU malnourished (3, 6, 28). Even children who are 
well nourished prior to their critical illness may develop acute 
protein–energy malnutrition within 48 h of PICU admission due 
to limited protein and energy reserves in the setting of severe 
acute illness (6, 32–35). In a study of 1622 mechanically ventilated 
children, underweight nutritional status based on admission 
BMI z-score was associated with an increase in hospital-acquired 
infections, fewer ventilator-free days, and lower likelihood of 
hospital discharge (Hazard ratio 0.71, p < 0.001) (Table 1) (26). 
These high-risk patients may benefit from personalized nutri-
tional strategies.
A growing percentage of children worldwide are now 
obese (39). While literature on the obese and critically ill 
pediatric patient is sparse, adult studies demonstrate a complex 
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relationship between obesity and clinical outcomes in critical 
illness and acute respiratory distress syndrome (ARDS) (40, 
41). While overall morbidity, including ventilator days and 
length of hospitalization, is higher, mortality was lower (40, 41). 
A mortality benefit may be due to a higher nutritional reserve in 
the setting of prolonged catabolism (40, 41). Similar to risks in 
underweight children, obesity based on admission BMI z-score 
is associated with higher risk of hospital-acquired infections 
and lower likelihood of hospital discharge (hazard ratio 0.82, 
p = 0.04) (26). It  is important to note, however, that obesity is 
not exclusive of malnutrition and that the obese child should 
receive the same consideration for nutritional supplementation 
(40). Both obese and underweight children are at increased risk 
compared with normal weight children for adverse outcomes 
while undergoing mechanical ventilation (26). For this reason, 
a nutritional support strategy should include early screening 
and diagnosis of malnutrition (42).
MACRONUTRieNT ReQUiReMeNTS 
DURiNG PeDiATRiC CRiTiCAL iLLNeSS
Protein
Protein requirements during acute illness are increased second-
ary to the catabolic state generated to support the production 
of acute phase proteins, repair of tissue, and the production of 
immune proteins (1). Protein demands can be increased by as 
much as 100% in severe sepsis, and even mild stressors, such as 
routine surgery, may increase protein needs by 25% (1). Infants 
who require extracorporeal membrane oxygenation have the 
highest reported rates of protein turnover in the literature (43, 
44). As discussed previously, prolongation of this catabolic state 
can result in decreased cardiopulmonary function secondary 
to breakdown of cardiac and respiratory muscle mass. While 
evidence currently suggests this catabolic process is not averted 
through protein intake but prevents recruitment of lean muscle 
mass as the major source of amino acids and increases protein 
production (44), and muscle mass can be preserved (45). Many 
adjuvant therapies, such as insulin for treatment of stress hyper-
glycemia, may be dependent upon adequate protein delivery to 
demonstrate efficacy. In 12 neonates on extracorporeal membrane 
oxygenation, Agus et al. found that improved protein balance as a 
result of insulin therapy was only seen in patients with adequate 
protein delivery (44). Liebau et al. was able to improve protein 
balance, but not protein breakdown, in 10 critically ill adults 
with sufficient enteral protein delivery (46). Concurrent supple-
mentation with adequate carbohydrate and lipid energy sources 
improves protein turnover and synthesis, thereby potentiating 
this counterbalancing (47). The decrease in protein breakdown 
seen with glucose supplementation in simple starvation does not 
decrease muscle catabolism for gluconeogenesis in the response 
to critical illness (47). Excessive protein administration should 
also be avoided as it can result in morbidity, such as azotemia, 
metabolic acidosis, and neurologic dysfunction, particularly as 
the patient improves and catabolic turnover subsides (48, 49). 
Recommended protein requirements in critically ill children 
vary by age and range from 3 g/kg/day in infants to 1.5 g/kg/day 
in adolescents (50).
energy
Energy sources in the form of lipids and carbohydrates are needed 
to facilitate protein synthesis and meet the patient’s total energy 
expenditure, which includes the energy needed for basal metabo-
lism, growth, physical activity, and thermogenesis. Critical illness 
induces an unpredictable metabolic state in children, which 
makes calculation of energy requirements challenging (51–53). 
Decisions regarding energy prescription are further complicated 
by the inherent variability both between patients and within the 
same patient over the course of their ICU stay, depending on 
ICU course and severity of illness (54–57). Age, anthropometric 
criteria, biochemical criteria, clinical exam, disease category, and 
stage of illness have all been demonstrated to be poor predictors 
of energy expenditure (51, 54). Other common factors that affect 
total energy expenditure and further complicate estimation are 
fever, sedation, temperature support, paralytics, and ventilator 
support. The variation in these factors requires frequent reassess-
ment and adjustment of nutritional support to accurately meet 
but not exceed the patient’s nutritional requirements.
Given the inaccuracy of estimating energy requirements and 
negative consequences of both over and underfeeding patients, 
PICU nutritional guidelines currently endorse precise and per-
sonalized determination of energy needs by indirect calorimetry 
(50). The ongoing physical growth and cognitive development 
of children suggest a need for early and adequate nutrition, sup-
ported by evidence that even short episodes of starvation during 
infancy result in permanent neurocognitive losses (29, 58, 59). 
One size does not fit most when it comes to delivery of calories 
and protein, and, in the absence of measured energy expenditure, 
patients may be easily misclassified as adequately fed when they 
are in fact over or underfed. This misclassification makes the rela-
tionship between energy adequacy and patient outcomes difficult 
to study. Indirect calorimetry is specifically recommended in the 
setting of outlier BMI (<5th percentile or >85th percentile), a 
>10% change in weight, prolonged ventilation, prolonged muscle 
relaxation, thermal injuries, oncologic diagnosis, or neurologic 
injury with dysautonomia (50). Indirect calorimetry is labor 
intensive, cannot be completed in all patients, and is poorly reim-
bursed but can be targeted to these high-risk populations, where 
precise nutritional support is likely to alter patient outcome (50). 
In the absence of measured resting energy expenditure, clinicians 
rely on predictive equations to assess calorie requirements and 
biomarkers to monitor for return of growth. Persistently elevated 
CRP and decreased prealbumin may indicate ongoing catabo-
lism, while normalization may reflect transition to an anabolic 
state with a concurrent increase in energy requirements (60, 61).
Current recommendations are that energy should be pre-
scribed as a balanced mixture of carbohydrates and lipids after 
appropriate provision of protein to preserve lean muscle mass (1). 
As previously discussed, the delivery of additional carbohydrates 
does not inhibit stress response gluconeogenesis and may result in 
hyperglycemia and its morbidities (poor wound healing, immune 
dysfunction, prolonged mechanical ventilation, and damage to the 
endothelial glycocalyx) (62–66). Lipid metabolism and turnover 
are increased in critical illness as fatty acids are used as a primary 
fuel source (64). Excessive carbohydrates are converted to lipids 
but generate carbon dioxide in the process, which may prolong 
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mechanical ventilation (60). Infants and children generally have 
limited fat stores and are susceptible to the development of essen-
tial fatty acid deficiencies as early as 1 week into critical illness, 
if not receiving sufficient lipids. Lipids are generally limited to 
30–40% of total calories. Balanced nutritional strategies provide 
sufficient macronutrients, while avoiding acute complications of 
excess protein, carbohydrate, and lipids.
ADeQUATe eNTeRAL NUTRiTiON iS 
ASSOCiATeD wiTH ReDUCeD 
MORTALiTY iN pARDS
evidence for early Nutritional Support
Prioritization of early EN is associated with improved tolerance 
of future EN and a reduction in morbidity from sepsis (3, 36). 
Murine studies demonstrated improved preservation of intestinal 
histoarchitecture and barrier function and improved local and 
remote organ immune function, with concurrent reduction in 
bacterial translocation and endotoxemia with the use of early 
EN (19, 67–70). Clinical research has demonstrated decreased 
mortality when EN is started within 48 h (30, 36). Specifically, 
one large study of >5000 patients with a PICU stay >96 h dem-
onstrated a decrease in mortality associated with provision of 
at least 25% of goal calories within 48  h (Table  1) (36). Adult 
studies have examined starting EN within 6 h of ICU admission 
without complication (71). These lines of evidence support the 
preferential use of EN in pARDS when it is safe to do so, a recom-
mendation supported by the 2015 Pediatric Acute Lung Injury 
Consensus Conference (72).
evidence for Dose of enteral Nutrition
Multiple retrospective studies demonstrate mortality benefit with 
improved adequacy of energy and protein provided during pedi-
atric critical illness (Table 1) (2, 3, 36). In a prospective, interna-
tional study of nutritional practices in 500 children ventilated for 
>48 h, Mehta et al. found that patients who received less than ⅓ of 
prescribed energy on average during the first 10 days after admis-
sion to the PICU had higher odds of mortality (3). An increase in 
prescribed energy by one tertile significantly decreased the odds 
of mortality. This relationship was only observed in patients with 
increased energy fed by the enteral route. ICUs, where a feeding 
guideline was in place, had overall lower hospital-acquired infec-
tion rates (3). Wong et al. examined 107 children with pARDS 
and identified that adequate energy and protein intake were 
associated with reduced mortality, while protein adequacy was 
also associated with increase ventilator-free days (4). These lines 
of evidence suggest that optimizing safe EN, rather than delivery 
of energy or protein via other routes of nutrition, is important for 
improving outcomes of pARDS.
Despite data regarding early nutritional adequacy and improved 
mortality, patients frequently fail to meet their calorie goals dur-
ing the first week of illness with median intake generally falling 
at 40–75% due to multiple barriers to provision of EN (3, 5–10). 
Mechanisms for poor patient outcome in the setting of under 
nutrition relate to both nutritive and non-nutritive sequelae of 
inadequate EN. Direct nutritive consequences to under nutrition 
are largely due to inadequate protein substrate for production 
of acute phase and immune proteins, with subsequent loss of 
lean body mass. This may lead to loss of both respiratory and 
cardiac muscle and difficulty with ventilator weaning (Figure 1). 
Non-nutritive benefits of EN include improved intestinal bar-
rier function, improved immune function, and maintenance of 
intestinal microbiome diversity. Appropriate targets to monitor 
these non-nutritive benefits are under development. Therefore, 
“optimal” nutrition can be defined in many ways depending on 
the target to define efficacy: sufficient energy and protein to meet 
metabolic demand, sufficient energy and protein to maintain 
lean body mass and functional recovery, sufficient energy and 
protein to maintain neurocognitive development, sufficient EN 
to maintain intestinal barrier functions, and adequate enteral 
composition to maintain microbiome diversity. The appropriate 
nutritional target in children with ARDS is not defined.
OveRFeeDiNG AND UNDeRFeeDiNG ARe 
ASSOCiATeD wiTH wORSe OUTCOMe iN 
PeDiATRiC CRiTiCAL iLLNeSS
Studies in adults and animals suggest negative impact of exces-
sive nutrition with difficulty with ventilator weaning and either 
a mortality benefit or non-inferiority with restricted caloric 
intake (Table  2) (73–79). Several retrospective studies in criti-
cally ill children identify overfeeding occurring in PICU patients 
with negative clinical consequences (53, 80). Overfeeding is 
associated with delayed ventilator weaning, lipogenesis, hepatic 
dysfunction, hyperglycemia, increased mortality, and prolonged 
hospitalization. Complications associated with underfeeding 
included delayed ventilator weaning, impaired protein synthesis, 
organ failure, and an increased risk of sepsis (7, 10, 24, 32). Several 
potential mechanisms exist for the negative impact of overfeeding 
on patient outcome, such as increase in carbon dioxide produc-
tion, increased intolerance of EN and parenteral nutrition (PN), 
refeeding syndrome, azotemia and metabolic acidosis from 
excess protein administration, hepatic steatosis from excess 
glucose delivery, hyperglycemia, hypertriglyceridemia, and on 
the cellular level the suppression of autophagy (53, 62, 81, 82). 
Administration of PN early in the course of critical illness may 
suppress autophagy, a necessary form of programmed cell death, 
which aids in removal of damaged proteins and mitochondria 
and is thought to play a role in recovery after organ failure (83).
ADULT iCU GUiDeLiNeS
American Society of Parenteral and Enteral Nutrition (ASPEN) 
Guidelines of the Provision and Assessment of Nutrition Support 
Therapy in the Adult Critically Ill Patient recommend that 
patients with ALI/ARDS receive either trophic or full EN over 
the first week of hospitalization. Even in adults, there is uncer-
tainty regarding timing and dose of nutrition therapy. Evidence 
exists that hypocaloric nutritional strategies, experienced by the 
majority of patients, may not benefit specific subsets of the criti-
cally ill, such as in the setting of mechanical ventilation, severe 
burns, and surgery (111–113). Patients at high nutritional risk, 
TABLe 2 | Key randomized, controlled trials in critical care nutrition 2006–2016.
Study Patient population intervention/comparison Outcomes
Dose, route, and timing
Parenteral nutrition
Fivez et al. (84) Multicenter RCT involving 1440 critically ill 
children
PN at 24 h versus 1 week (EN initiated in both groups) No difference in mortality. Fewer infections in late PN (10.7 versus 
18.5%) group, shorter duration of mechanical ventilation (p = 0.001), 
fewer patients required renal replacement therapy (p = 0.04), shorter 
ICU stays (p = 0.001)
Harvey et al. (85) Multicenter RCT of 2400 critically ill adults Early PN versus Early EN up to 5 days after ICU admission  
in adults who could be enterally fed
No difference in 30- (33.1 versus 34.2%, p = 0.57) or 90-day 
mortality (p = 0.4). Reduced hypoglycemia, vomiting in the early PN 
group. No difference in treated infectious complications
Doig et al. (86) Multicenter RCT of 1372 critically ill adults Early PN versus standard care for patients with relative 
contraindications to early EN
No difference in 60-day mortality (21.5 versus 22.8%, p = 0.6). 
Early PN patients required fewer days of mechanical ventilation and 
experienced less muscle wasting
Heidegger et al. (87) Multicenter RCT of 153 critically ill adults 
meeting <60% of caloric needs by EN on ICU 
day 3
Supplemental PN versus EN alone on days 4–8 Supplemental PN associated with higher percentage of energy target 
and fewer nosocomial infections
Casaer et al. (88) Multicenter RCT of 2328 critically ill adults PN at 48 h versus 1 week (EN initiated in both groups) No difference in mortality. Fewer ICU infections (22.8 versus 26.2%, 
p = 0.008) in late PN group, smaller proportion of patients with 
>2 days of mechanical ventilation, median reduction of 3 days for 
renal replacement therapy (p = 0.008)
Dose of macronutrients
Arabi et al. (89) Multicenter RCT of 894 critically ill adults Permissive underfeeding of non-protein calories (40 to 60%  
of goal) versus standard enteral feeding (75–100% of goal)
No difference in 90-day mortality (27.2 versus 28.9%, RR 0.94). 
No significant between-group differences for feeding intolerance, 
diarrhea, ICU-acquired infections, or length of stay
Braunschweig  
et al. (90)
Single-center RCT of 78 adults with acute 
lung injury
Intensive medical nutrition (>75% goal) versus standard  
nutritional support (~55% goal)
Significantly greater hospital mortality in intensive group (40 versus 
16%, p = 0.02)
Rice et al. (91) Multicenter RCT of 1000 adults with acute 
lung injury
Early trophic versus full enteral feeding No difference in 28-day ventilator-free days (14.9 versus 15.0, 
p = 0.89) or 60-day mortality (23.2 versus 22.2%, p = 0.77). No 
differences in infectious complications between the groups. Initial 
trophic feeds were associated with less feeding intolerance
Gastric versus post-pyloric feeds
Davies et al. (92) Multicenter RCT of 181 critically ill and 
intubated adults with elevated gastric residuals
Continuation of gastric feeds versus transition to post-pyloric  
feeds
No clinically significant difference
Acosta-Escribano et al. 
(93)
Single-center RCT of 104 adults with severe 
traumatic brain injury
Gastric versus post-pyloric feeds Lower incidence of pneumonia in post-pyloric groups OR 0.3 (95% CI 
0.1–0.7, p = 0.01) and higher percentage of nutrional needs met (92 
versus 84%, p < 0.01)
Hsu et al. (94) Single-center RCT of 121 critically ill adults Gastric versus post-pyloric feeds Post-pyloric feeds associated with earlier achievement of nutritional 
goals, less vomiting, and less pneumonia
Early enteral nutrition
Khorasani and 
Mansouri (95)
Single-center RCT of 688 burned children EN at 3–6 h versus at 48 h Early EN associated with decreased length of stay and mortality (12 
versus 8.5%, p < 0.05)
Continuous versus bolus enteral nutrition
MacLeod et al. (96) Single-center prospective RCT of 164 critically 
ill adult trauma patients
EN as q 4 h boluses versus continuous drip Intermittent regimen reached goal quicker with no difference in 
complications
Glycemic control
NICE-SUGAR study 
investigators et al. (97)
Multicenter RCT of 6104 critically ill adults Intensive glucose control (81–108 mg/dL) versus conventional 
contol (<180 mg/dL)
Higher mortality (OR 1.14; 95% CI, 1.02–1.28; p = 0.02) and more 
hypoglycemia (6.8 versus 0.5%, p < 0.001) in the intensive group
(Continued)
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Study Patient population intervention/comparison Outcomes
Vlasselaers 2009 (98) Single-center RCT of 317 critically ill infant and 
383 critically ill children (700 total)
Intensive normoglycemia with target glucose 50–79 (infant)/ 
70–100 (children) versus target glucose <214 mg/dL
Lower mortality (3 versus 6%, p = 0.013) despite more hypoglycemia 
(25 versus 1%, p = 0.001) in the intensive group
Van den Berghe et al. 
(99)
Single-center RCT of 1200 critically ill adults 
(medical)
Intensive glucose control (80–110 g/dL) versus conventional  
control (<180 mg/dL)
No difference in mortality but decreased acute kidney injury (5.9 
versus 8.9%, p = 0.04), earlier weaning from mechanical ventilation 
(p = 0.03), and shorter hospital stay in intensive group (p = 0.05)
immune modulation
Glutamine and selenium, antioxidants
Ziegler et al. (100) Multicenter RCT of 150 critically ill adults Alanyl–glutamine dipeptide (0.5 g/kg/d), proportionally replacing 
amino acids in PN versus standard PN (EN initated as tolerated)
No difference in clinical outcomes
Pérez-Bárcena et al. 
(101)
Multicenter RCT of 142 critically ill adults 
(trauma)
l-alanyl–l-glutamine dipeptide (0.5 g/kg body weight/day) 
supplementation for 5 days versus standard PN
No difference in clinical outcomes
Heyland et al. (102) Multicenter RCT of 1223 critically ill adults (l-alanyl–l-glutamine dipeptide at 0.5 g/kg body weight/day 
PN supplementation and 42.5 g of alanyl–glutamine and  
glycine–glutamine dipeptides EN supplementation) versus  
(500 μg of selenium intravenously + 300 μg of selenium, 20 mg of 
zinc, 10 mg of beta carotene, 500 mg of vitamin E, and 1500 mg 
of vitamin C orally) versus combination versus placebo
Higher mortality in those receiving glutamine (OR 1.28, CI 1.00–1.64, 
p = 0.05)
Carcillo et al. (103) Multicenter RCT of 293 critically ill children Enteral zinc, selenium, glutamine and IV metoclopramide (ZSGM) 
versus enteral WHEY protein and IV saline up to 28 days of ICU 
stay
No differences in time until first episode of nosocomial infection/
sepsis (median WHEY 13.2 days versus ZSGM 12.1 days, p = 0.29) 
or the rate of nosocomial infection/sepsis (4.83/100 days WHEY 
versus 4.99/100 days ZSGM, p = 0.81)
Andrews et al. (104) Multicenter RCT of 502 critically ill adults Parenteral glutamine (20.2 g/day) or selenium (500 μg/day)  
or both for up to 7 days versus placebo
No affect on new infections or mortality except for a reduction in 
infections for patients receiving selenium for 5 or more days (OR 0.53, 
CI 0.30–0.93).
Angstwurm et al. (105) Multicenter RCT of 189 adults with severe 
sepsis/SIRS
Selenium as 1000 μg of sodium-selenite over 30 min followed by 
continuous infusions of 1000 μg daily for 14 days versus placebo
Reduced mortality in the selenium group (OR 0.56; CI 0.32–1.00, 
p = 0.049)
Omega-3 fatty acids alone or in combination
Grau-Carmona et al. 
(106)
Multicenter RCT of 159 critically ill adults Total PN with a lipid emulsion containing 10% fish oil versus  
a fish oil-free lipid emulsion
Fish oil emulsion associated with decreased nosocomial infections 
(21.0 versus 37.2%, p = 0.035)
Kagan et al. (107) Single-center RCT of 120 critically ill adults 
(trauma)
EN enriched with eicosapentaenoic acid, γ-linolenic acid, and 
antioxidants versus a non-enriched control formula initiated at time 
of admission
No significant difference in clinical outcomes
van Zanten et al. (108) Multicenter RCT of 301 intubated adults EN enriched with glutamine, omega-3 fatty acid, and antioxidants 
(experimental product, NV Nutricia, Zoetermeer) versus high-protein 
tube feed (Nutrison Advanced Protison, NV Nutricia, Zoetermeer)
No difference in infection rate and increased 6-month mortality 
associated with immunomodulatory EN (35 versus 54%, p = 0.04)
Jacobs et al. (22) Multicenter RCT of 26 critically ill children with 
acute lung injury
EN supplemental with eicosapentaenoic acid, γ-linolenic acid, and 
antioxidants versus standard EN
Improved biochemical profile
Pontes-Arruda et al. 
(109)
Multicenter RCT of 115 critically ill adults Immunomodulator EN with eicosapentaenoic acid and γ-linolenic 
acid (Oxepa) versus standard EN (Ensure Plus HN)
No significant difference in mortality but immunomodulatory EN 
associated with decreases in the severity of sepsis, cardiovascular 
failure, respiratory failure, mechanical ventilation, and length of stay
Radrizzani et al. (110) Multicenter RCT of 326 critically ill adults Immunomodulatory EN (Perative, 55% carbohydrate, 25% fat, 
21% protein, 1.3 kcal/mL, containing per 100 mL: 0.8 g l-arginine, 
0.15 g ω-3 fatty acids, 0.7 g ω-6 fatty acids, 2.9 mg vitamin E, 
0.75 mg β-carotene, 2.2 mg zinc, and 7 μg selenium) versus PN 
(containing 59% carbohydrate, 23% fat, 18% protein, 1.2 kcal/mL)
No difference in mortality. Immunomodulatory EN associated with 
decreased progression to severe sepsis or septic shock (4.9 versus 
13.1%, p = 0.022) and shorter ICU length of stay
TABLe 2 | Continued
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defined as either undernourished or overnourished at baseline 
may benefit from a more aggressive nutritional strategy (114). 
The intensive nutrition in acute lung injury (INTACT) study was 
designed to deliver >75% of goal energy and protein needs daily 
to adult ICU patients via EN from date of diagnosis of ARDS to 
hospital discharge as compared with standard nutrition support 
(Table 2) (90). The INTACT study found increased mortality (40 
versus 16%, p = 0.02) with aggressive nutritional support (85% 
of estimated energy expenditure) when compared with standard 
therapy (55% of estimated energy expenditure) and was stopped 
early (90). While impossible to apply directly to pediatric patients 
due to their different metabolic needs and ongoing growth and 
neurocognitive development, these data reinforce the powerful 
role nutrition exerts on patient outcome and highlight the need 
for rigorous research to identify the optimal timing and dose 
of calories and protein, tailored to narrowly defined patient 
populations.
Individualized nutritional therapies that are “just right” and 
meet, but do not exceed, needs are currently recommended 
by ASPEN guidelines for nutritional prescription in critically 
ill children (50). “Optimal” energy and protein targets remain 
elusive, and response to nutrition delivery is likely related to 
baseline nutritional risk and current diagnosis. Increased 
utilization of non-invasive ventilation (NIV) in pARDS is asso-
ciated with worse nutritional adequacy, and nutrition-related 
outcomes for patients managed with NIV are unknown (115). 
We do not know if potential benefits to NIV are outweighed 
by risks related to underfeeding. Underfeeding is harmful, 
but overfeeding is equally harmful. Multiple clinical trials are 
criticized for comparing very underfed to underfed patients, or 
for overfeeding patients. At the heart of these controversies lies 
the difficultly in determining in real-time calorie and protein 
needs and response to nutritional intervention. Advances in 
body composition assessments that are practical during pARDS 
in ultrasound, bioelectrical impedance, CT imaging, and func-
tional outcomes assessments to monitor lean body mass close 
monitoring of lean body mass during pARDS a possibility, but 
require further study (116–119).
ROUTe OF NUTRiTiON
evidence for Gastric versus Post-pyloric 
Feeds
The decision to prescribe gastric or post-pyloric EN has limited 
evidence to provide guidance. A study of 74 critically ill children 
randomly assigned to gastric or post-pyloric feeds demonstrated 
no difference in complications, and patients receiving post-
pyloric feeds received more of their prescribed calories (120). 
A  large meta-analysis of adult patients with severe traumatic 
brain injury demonstrated a decreased risk of pneumonitis with 
post-pyloric feeds (121). Other researchers found an increased 
risk of gastrointestinal complications when post-pyloric feeds 
were used in septic patients or patients on epinephrine (Table 1) 
(37, 122). Institution-based policies regarding verification of 
enteral feeding tube position, particularly for post-pyloric feeds, 
may result in significant delays in initiation of feeds. No studies, 
so far, have specifically evaluated gastric versus post-pyloric feeds 
in the setting of pARDS.
evidence Regarding Parenteral Nutrition
Current standard practice in the US is to reserve PN for 
situations in which EN fails or is not possible. This practice 
is rooted in retrospective evidence linking PN to increased 
risks of sepsis and mortality when compared with EN alone 
(3). Unfortunately, the evidence to guide clinical decisions is 
limited by current practice patterns. Because PN is reserved 
for the sicker patient who cannot tolerate EN, retrospective 
studies are likely confounded by variables that predict both 
increased PN use and mortality. The Pediatric Early versus Late 
Parenteral Nutrition in Intensive Care Unit (PEPaNIC) study 
was an international, multicenter, randomized, and controlled 
trial comparing early versus late initiation of PN in critically 
ill children (Table  2) (123). The PEPaNIC Trial tested the 
relationship between early and later PN supplementation in 1440 
children from newborn to 17 years of age and found no differ-
ence in mortality between the two groups (84). This study was 
not limited to children with pARDS. A significantly increased 
rate of hospital-acquired infections (18.5 versus 10.7%) was 
present in patients in the early PN group as compared with 
the late PN group (84). However, characteristics of the study 
design limit the generalizability of this study to pARDS patients. 
The macronutrient dose was not controlled in the study, and 
central line utilization was not reported in experimental and 
control groups. The study patients were heterogeneous, and 
not exclusive to pARDS. Questions remain whether early PN 
is of benefit in pARDS. The potential benefit and/or harm from 
early PN is unclear, and the current clinical focus is to provide 
sufficient energy and protein preferentially by the enteral route 
until further studies are completed.
Research in neonatal intensive care unit supports the early use 
of at least low rates of EN to support bowel health in combina-
tion with PN to meet metabolic needs with the added advantage 
of fewer interruptions in nutrient delivery when PN is used 
(124). The use of this combination therapy, beginning with the 
first hours to days of life in preterm infants, has been associated 
with improved growth, improved neurodevelopment, improved 
EN tolerance, and decreased morbidity at both intermediate 
(18 months) and long-term (5 year) follow-up (30, 58, 59, 125). 
It remains unclear if older or term infants with ARDS might 
benefit from a similar early PN strategy with regard to short-term 
clinical and long-term neurocognitive outcomes. Research in the 
adult patient population have demonstrated mixed results with 
regard to days of mechanical ventilation and morbidity, such as 
infection and renal insufficiency (78, 86, 88). This is consistent 
with previous literature suggesting improved outcomes with 
calorie restriction in the adult population (78). Given the ongoing 
growth and development of pediatric patients, it is reasonable to 
question whether combination therapy with EN and PN in chil-
dren with pARDS will see similar benefits to those demonstrated 
in the NICU population. Despite the results of the PEPaNIC 
study, equipoise remains in the pARDS population. The optimal 
macronutrient dose, timing, and formulation of EN and PN sup-
port has yet to be elucidated as increasing evidence demonstrates 
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links between the immune system, homeostasis, and nutritional 
intake (121, 126–129).
Barriers to Nutritional Support
Barriers to adequate EN can be broadly categorized as medical 
contraindication, prescriber discomfort, and frequent interrup-
tion (7, 9, 130, 131). Subjective rather than objective decision-
making continues regarding decisions to initiate, advance, or 
maintain EN. Medical contraindications can include a need for 
volume restriction, hemodynamic instability, and ill-defined 
feeding intolerance. Studies in hemodynamically unstable adults 
requiring vasopressors demonstrated lower mortality with early 
EN (132). While large database studies do not demonstrate 
increase in adverse intestinal outcomes in children fed enter-
ally while on vasoactive infusions, children with hemodynamic 
instability who do experience complications of EN have worse 
outcomes than children not fed by the enteral route (38, 122). 
Provider concerns regarding complications of EN in the setting of 
hemodynamic instability are warranted (122). Research is needed 
to further clarify the risks of EN while on vasoactive infusions, to 
identify optimal dosing strategies in the setting of hemodynamic 
instability, and to develop biomarkers to monitor safety of EN 
so that we might minimize risk, minimize unnecessary practice 
variation, and maximizing EN to patients at low risk of intestinal 
complications.
Feeding intolerance is the most frequent cause of interrup-
tion to EN, particularly in the current practice environment of 
deferring PN in marked preference for full EN. There is immense 
variability in clinician assessment of feeding intolerance and 
frequently used clinical criteria, such as bowel sounds, abdomi-
nal exam, gastric residual volumes, and lactate levels have not 
been validated (9, 130, 133, 134). Feeding intolerance occurs in 
43–57% of critically ill children (9, 135). Even the definition of 
feeding intolerance is widely variable, and the natural history of 
bowel function in critical illness is yet to be fully elucidated (136, 
137). Delayed gastric emptying and poor intestinal motility are 
causes of feeding intolerance, and, if left untreated, are impedi-
ments to achievement of goal EN. Delayed gastric emptying 
occurs in up to 50% percent of critically ill children, yet remains 
under recognized as a source of feeding intolerance (138). 
Promotility agents are commonly used for both gastric and 
intestinal dysmotility during pediatric critical illness, but only 
erythromycin and metoclopramide are currently approved in the 
US. Newer promotility agents, such as cholecystokinin receptor 
antagonists, ghrelin, and methylnaltrexone, in the setting of 
opioid-induced dysmotility, require further research in children 
with pARDS, but show promise to improve EN tolerance (138, 
139). The development of validated tools for the diagnosis and 
monitoring of feeding intolerance represents an opportunity 
to significantly improve care in PICU patients by decreasing 
barriers to nutritional support. Biomarker-based guidelines 
for the initiation, advancement, and maintenance of EN are 
under development (140). Depending on hospital policies and 
local practice patterns, procedures are also a frequent cause 
of held EN and interruption of nutritional support despite an 
absence of data to guide these decisions (9). NIV and intensive 
therapies, such as extracorporeal membrane oxygenation, are in 
particular associated with nutritional interruption (141, 142). In 
adult ICU’s, improved nutritional adequacy is reported when 
volume-based daily feeds are ordered, rather than an hourly 
rate (143). Volume-based orders accommodate 4–6  h of NPO 
status daily with the volume of EN delivered over 18–20 h, but 
larger studies are needed to understand the clinical outcome of 
a volume-based EN strategy in pARDS. A currently enrolling 
clinical trial, continuous versus bolus nasogastric feeding for 
mechanically ventilated pediatric patients (Clinical Trials ID: 
NCT02566070), will evaluate feeding intolerance and nutritional 
adequacy with two gastric feeding strategies. Consideration 
should be given to early initiation of a bowel regimen to prevent 
constipation and subsequent feeding intolerance while avoiding 
diarrhea and malabsorption. Implementation of an early EN 
guideline improved percent of goal energy and protein achieved 
in multiple retrospective studies, likely due to perceived empha-
sis on nutrition in a particular PICU (144, 145).
Glycemic Control
Literature in the adult population demonstrated compelling early 
evidence for significant decreases in morbidity and mortality 
with tight glycemic control (146). Subsequent research has dem-
onstrated no benefit, but these results are drawn into question by 
large differences in mean glucose level and the use of point-of-care 
glucose testing rather than the arterial blood gas analysis used in 
the initial study (147–149). The negative impact of poor glycemic 
control is supported by current pediatric research, but the ideal 
target for blood glucose ranges has yet to be established (98, 150). 
The Heart And Lung Failure – Pediatric INsulin Titration (HALF-
PINT) trial (Clinical Trials ID: NCT01565941) is a multicenter, 
randomized clinical treatment trial comparing effectiveness of 
tight glycemic control to a target range of 80–110 mg/dL versus a 
target range of 150–180 mg/dL.
THe GUT AS THe MOTOR FOR ARDS
There are many research opportunities to improve nutritional 
supplementation for critically ill patients in general as well 
as specifically within the framework of pARDS. Emerging 
research continues to demonstrate the role of gut dysfunc-
tion in the development of ARDS (13, 151). Deitch proposed 
the “gut lymph” hypothesis, whereby, the injured gut allows 
translocation of bacteria and bacterial products and liberates 
cytokines and chemokines, which act via the lymphatic duct to 
activate alveolar macrophages and contribute to pathogenesis of 
ARDS (152). Clark and Coopersmith proposed the “intestinal 
crosstalk” theory whereby the intestinal microbiota, immune 
system, and intestinal epithelial barrier interact and, when 
dysregulated, worsen systemic inflammation (153–155). Loss 
of balance in this “crosstalk” may lead to ARDS and is sup-
ported by emerging animal and human data examining the 
microbiome in critical illness. Modulation of intestinal barrier 
function and microbiome remain novel targets to improve 
outcomes in pARDS.
Several minimally invasive plasma biomarkers show promise 
in guiding initiation, titration, and continuation of EN by objec-
tively assessing intestinal epithelial structure and function as 
TABLe 3 | Minimally invasive plasma biomarker candidates to assess 
intestinal barrier function.
Biomarker Site specificity Relevant data
Intestinal fatty 
acid-binding 
protein (I-FABP 
or FABP2)
Enterocytes of 
the small and 
large intestine
Plasma concentration correlates with 
histological phases of enterocyte injury 
after ischemia-reperfusion and is a marker 
of acute enterocyte damage (156, 157). 
Predictive of poor outcome if elevated 
after refeeding infants with NEC (158)
Liver fatty acid-
binding protein 
(L-FABP)
Enterocytes of 
the small and 
large intestine, 
hepatocytes
Plasma concentration discriminates 
infants with sepsis versus NEC (162)
Claudin 3 Apical tight 
junction  
complex
Strong correlation between plasma 
claudin 3 and enterocyte tight junction 
loss in rat hemorrhagic shock model, 
human necrotizing enterocolitis (163, 164). 
Ubiquitous in lung tight junctions but lung 
injury does not cause elevation in plasma 
levels
Citrulline Mature 
enterocytes of 
small intestine, 
colon
Manufactured in mitochondria of mature 
enterocytes. Validated as a biomarker 
for functional enterocyte mass in short 
bowel syndrome, HIV patients, stem cell 
transplant patients, graft-versus-host 
disease, and in children after bowel 
resection (165–171)
Trefoil Factor 3 Intestinal goblet 
and mucin cells
Differentiates between surgical and 
non-surgical NEC in preterm infants and 
assess disease activity in inflammatory 
bowel disease (162, 172)
NEC, necrotizing enterocolitis; HIV, human immunodeficiency virus.
10
Wilson and Typpo Nutrition in Pediatric ARDS
Frontiers in Pediatrics | www.frontiersin.org October 2016 | Volume 4 | Article 108
well as assessing for the translocation of bacteria and bacterial 
products (Table 3) (156–158). The intestinal epithelial barrier is 
a single-cell monolayer tasked with competing roles to absorb 
nutrients, interact with commensal organisms, and limit entrance 
of pathogens and their products (Figure  2) (159, 160). It is 
the largest surface in the body in contact with the external 
environment. Intestinal barrier dysfunction is associated with 
the pathogenesis of multiple organ dysfunction, translocation 
of bacteria and endotoxin, and loss of remote organ immune 
function (19, 159, 161). Enteral feeding of at least 15% of goal 
calories restores intestinal barrier function in murine models 
of critical illness (69). The minimum dose of EN required to 
maintain intestinal barrier function in children with pARDS 
is unknown. Biomarkers to monitor intestinal barrier function 
could guide provider decisions regarding the minimum neces-
sary dose of enteral feeding. In a study of 20 children after car-
diopulmonary bypass, biomarker concentrations were associated 
with symptoms of feeding intolerance (140). Biomarker-based 
decision rules for initiation, advancement, and maintenance of 
EN represent an opportunity to reduce practice variation and 
improve success in achieving and maintaining nutritional goals. 
The development of biomarkers to accurately and easily measure 
the catabolic and anabolic balance of the metabolic system is 
another area of ongoing research which will assist clinicians to 
more accurately develop nutritional prescriptions (46).
iNTeSTiNAL MiCROBiOMe MAY SHAPe 
iMMUNe ReSPONSeS
Technological advances in computing power and analytic 
techniques over the last decade make the study of the human 
microbiome possible (173). In the human body, bacterial cells 
exceed human cells in number and perform many essential func-
tions, such as production of short chain fatty acids and vitamins 
(vitamin K), which aid the human host (174). The developmental 
maturation of the human microbiome is poorly understood, but it 
reaches adult patterns by 2–4 years of age (175). Dysbiosis occurs 
when the symbiotic relationship between human and microbial 
populations is disturbed and may result in reduced microbiome 
diversity. Reduced microbiome diversity during infancy, a critical 
time period during microbiome development, may have lasting 
consequences on the development of several chronic diseases 
(176). Murine models where antibiotics are provided during 
infancy, demonstrate rapid and permanent alteration of metabolic 
phenotype via transient reduction in intestinal microbiome diver-
sity (176–178). In contrast, an increased microbiome diversity in 
human infants enhances maturation of the intestinal mucosal 
immune system, which can influence LPS responsiveness at 1 year 
of age in humans (179). Thus, normal metabolic and immune 
imprinting by essential “keystone” microbes, which can be altered 
by early antibiotic exposures, may have long-term consequences 
on immune response to critical illness and risk of chronic illness. 
This emerging field has the potential to shift our targets with 
regard to control of both acute and chronic inflammation from 
modulation of human cells to modulation of the bacterial within 
us. The gastrointestinal microbiota is implicated in control of 
inflammation in the lung (180). Diet is a potent determinant of 
intestinal microbiome diversity and, in murine models, trumps 
genetic background (181). Carmody et  al., demonstrated, in a 
murine model, that rapid changes in diet resulted in rapid shifts in 
microbial composition (181). As diet is an essential determinant 
of microbiome diversity and alters lung inflammation, dietary 
manipulation of the gastrointestinal microbiome may be a new 
target for treatment of pARDS. We do not know how medical 
diets alter the intestinal microbiome during pARDS, nor do we 
understand the short or long-term consequences of nutritional, 
probiotic, or pre-biotic interventions.
iMMUNONUTRiTiON
Immunonutrition is well tolerated and results in improved 
pro-inflammatory cytokine profiles, but is not associated with 
clear clinical outcome benefits (182). While small single-center 
studies of isolated pharmaconutrients showed promise, multiple 
combination nutritional and pharmacologic additives in critically 
ill adults aimed at modulating the inflammatory and immune 
response have not shown benefits (Table 2) (183, 184). Specific 
supplements that have been explored include several anti-
oxidants, arginine, glutamine, metoclopramide, ω-3 fatty acids, 
zinc, and selenium (103, 185–190). The randomized comparative 
effectiveness pediatric critical illness stress-induced immune 
suppression (CRISIS) prevention trial examined the effect in 
critically ill children of daily enteral zinc, selenium, glutamine, 
FiGURe 2 | Theoretical framework to maintain intestinal barrier dysfunction in pARDS. EN, enteral nutrition; SIRS, systemic inflammatory response 
syndrome; CARS, compensatory anti-inflammatory response syndrome. Primary determinants of intestinal barrier function are the apical tight junction complex and 
the intestinal epithelial cells. Modifiable clinical factors known to modulate intestinal barrier function include EN and antimicrobials. Specific targets for perfusion and 
oxygenation to improve intestinal barrier function in the setting of pARDS are unknown. The balance of forces will lead to intestinal barrier (A) function or (B) 
dysfunction and a downstream clinical phenotype with either improved or worsened remote organ (lung) function.
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and IV metoclopramide on incidence of nosocomial infections. 
No difference was seen between the two groups, and the trial was 
stopped early due to futility (103). Multiple combination nutri-
tional and pharmacologic additives in critically ill adults aimed 
at modulating the inflammatory and immune response have been 
trialed, but have generally not shown any benefits (50, 191). The 
optimal formulation of lipids is an area of active research with 
continued focus on the role of ω-3 polyunsaturated fatty acids 
(PUFAs).
OMeGA-3 POLYUNSATURATeD 
FATTY ACiDS
The use of ω-3 PUFAs as a nutritional adjuvant have evidence sug-
gesting they may reduce the pro-inflammatory state in ARDS, but 
a recent systematic review and meta-analysis looking specifically 
at ARDS patients in the adult ICU found no benefit in clinical 
outcomes (107, 192–197). The rationale for ω-3 PUFAs is that 
they may be beneficial in ARDS as they would compete with ω-6 
PUFAs, decrease the synthesis of pro-inflammatory eicosanoids, 
increase production of anti-inflammatory lipid mediators, such 
as resolvins and protectins, decrease in chemotaxis, decrease 
reactive oxygen species (ROS) and pro-inflammatory cytokines, 
and decrease leukocyte binding and activation through decreased 
expression of adhesion molecules (Figure 3) (192).
Jacobs et  al. evaluated the feasibility of ω-3 PUFAs (eicosa-
pentaenoic acid +  γ-linolenic acid) in children with ALI and 
ARDS and examined the impact of ω-3 PUFAs on plasma phos-
pholipid fatty acid concentrations (22). They found that delivery 
of nutrition enriched with eicosapentaenoic acid + γ-linolenic 
acid was feasible and resulted in an anti-inflammatory fatty acid 
profile (22). This study is supportive of future work in this area 
in children. Whether a change in anti-inflammatory fatty acid 
profile will improve clinical outcomes is unclear, but promising. 
Methodological challenges in several adult trials limit conclu-
sions regarding ω-3 PUFAs in adult patients with ARDS (192). 
Specifically, studies are heterogeneous, and, in some, the control 
diet was pro-inflammatory.
Several ω-3 PUFA-derived mediators are potential targets 
to resolve the inflammatory response in the setting of pARDS 
(Figure  3). Alveolar edema and neutrophil recruitment and 
activation are early events in ARDS. Resolvins, protectins, and 
maresins are lipid-derived mediators, and several resolvins are 
emerging as potential therapeutic targets for resolution of ARDS 
(Figure  3) (20, 21). These resolvins are derived from the ω-3 
PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA). Eickmeier et  al. found that aspirin-triggered resolvin 
D1 reduces mucosal inflammation and promotes resolution in 
a murine model of acute lung injury (21). Aspirin-triggered RV 
D1 decreased lung inflammation and promoted acute lung injury 
FiGURe 3 | Pathways of selected downstream lipid mediators derived from arachadonic acid (AA), docosahexaenoic acid (DHA), and 
eicosapentaenoic acid (ePA) for resolution of acute inflammation. DHA and EPA are ω-3 fatty acids. Adapted with permission from Serhan and Petasis (198); 
PGD2, prostaglandin D2; PGE2, prostaglandin E2; LTC4, leukotriene C4; LTB4, leukotriene B4; LXA4, lipoxin A4; AT-LXA4, aspirin-triggered lipoxin A4; RvE1, 
resolvin E1; RvE2, resolvin E2; RvD1, resolvin D1, RvD2, resolvin D2; PD1, protectin D1; MaR1, maresin 1.
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resolution shortly after injury in an hydrochloric acid model of 
ARDS by enhancing restitution of barrier integrity, decreasing 
circulating neutrophil–platelet heterotopic interactions, and 
regulating inflammatory mediators and nuclear factor-κB (NF-
κB) activation (21). Seki et al. found that resolvin E1 protected 
mice from bacterial pneumonia and acute lung injury with pre-
treatment by decreased lung neutrophil accumulation, enhanced 
microbial clearance, decrease in lung pro-inflammatory media-
tors, and improved survival (20).
viTAMiN D
Recent evidence suggests an association between vitamin D 
levels and the risk of ARDS (199–201). Vitamin D deficiency 
is associated with impaired pulmonary function and increased 
incidence of viral and bacterial infections and inflammatory 
disease, including asthma and COPD (202–204). Mechanisms 
for these associations are unknown, but vitamin D plays a role in 
macrophage, lymphocyte, and epithelial cell function, critical to 
ARDS pathophysiology (200, 205).
SUMMARY
There are currently limited data to guide nutritional strategies in 
the critically ill pediatric patient and an absence of data targeted 
specifically at pARDS (Tables 2 and 3). Current strategies rely 
on the application of adult data, knowledge of the metabolic 
derangements caused by critical illness, and knowledge of the 
nutritional requirements of healthy children. The generally 
accepted strategy centers on the early identification of need for 
nutritional supplementation and early initiation of EN targeted 
toward fulfillment of nutritional goals and implemented by a 
collaborative, multidisciplinary treatment team. Indirect calo-
rimetry is a recommended adjunct to ensure adequate, but not 
excessive, nutritional support is supplied. Early prescription of 
a bowel regimen to limit constipation while avoiding diarrhea 
is also recommended (50). PN is currently reserved for patients 
in whom EN is contraindicated or limited, though its routine 
use as a supplement to EN is an area ripe for research. Before 
we evaluate the role of immunonutrition to improve outcomes 
of pARDS, fundamental questions regarding protein and 
energy requirements during pARDS remain: if delivery should 
be based on premorbid nutritional risk and if under, normo, 
or even overfeeding might be beneficial at different stages of 
illness. Given the mortality benefit of nutritional adequacy on 
pARDS, it may prove challenging to identify benefits of adjuvant 
nutritional therapies, unless they are overlaid upon a foundation 
of adequate macronutrient delivery. Once fundamental questions 
regarding optimal timing, dose, and route of macronutrient 
delivery are answered for pARDS, investigations centered on 
immunonutrition to further improve patient outcomes are 
appropriate. Systematic investigations to determine the impact 
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of each pharmaconutrient separately and in combination during 
pARDS are necessary.
In the future, intensivists will likely employ distinct and 
highly personalized nutritional therapies based on patient pre-
morbid nutritional risk, admission diagnosis, severity of illness, 
measured energy expenditure, active monitoring of lean body 
mass, and the composition of patient intestinal microbiome. A 
select group of high-risk patients are likely to experience benefit 
from an intensive and personalized, titrated nutritional plan. 
Long-stay patients, patients with ARDS, sepsis, burns, or pre-
existing severe malnutrition are most likely to have improved 
outcomes if nutrition is closely monitored. Intensive nutritional 
therapies will likely be titrated daily to meet energy and pro-
tein needs. Nutritional therapies, monitoring, and impact on 
meaningful patient outcomes are likely to change dramatically 
in the next decade as we understand the role of the microbiome 
in regulating both intestinal health and also the inflammatory 
response to pARDS. We may require nutritional or “metabolic” 
teams to precisely tailor metabolic support to meet, but not 
exceed, energy, protein, and micronutrient needs, preserve lean 
body mass, the microbiome, the virome, and intestinal barrier 
functions. Nutrition is fundamental to provision of critical 
care services, and, with an understanding of the complex role 
it plays in illness and health, we will be able to design effective 
clinical trials of nutritional interventions as primary therapies 
for pARDS.
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